Firms

Codon Capital

codoncapital.com

Codon Capital is an early-stage biotechnology investor led by founder and managing partner Karl Handelsman. It backs teams developing differentiated therapeutic technologies and helps scientists and entrepreneurs turn research into companies. Disclosed investments include EpiBiologics’ extracellular protein degradation, Bonum Therapeutics’ conditionally active biologic medicines, Seismic Therapeutic’s machine-learning-assisted immunology programs, and AIRNA’s RNA-editing therapies.

Founded

—

Type

Venture capital

Team

Co-investing

Digitalis Ventures

• EpiBiologics$107M · 2026-01-08
• EpiBiologics$23M · 2023-07-20
• Bonum Therapeutics$93M · 2022-11-15

Taiho Ventures

• EpiBiologics$107M · 2026-01-08
• EpiBiologics$23M · 2023-07-20

Vivo Capital

• EpiBiologics$107M · 2026-01-08
• Bonum Therapeutics$93M · 2022-11-15

503 Partners (formerly 3x5 Partners)

• Bonum Therapeutics$93M · 2022-11-15

Aulis Capital

• EpiBiologics$107M · 2026-01-08

SHOW MORE

Investments

$107M2026-01-08	EpiBiologics	GV, Johnson & Johnson Innovation – JJDC, Novartis Venture Fund, Avego BioScience Capital, Samsara BioCapital, Polaris Partners, Digitalis Ventures, Taiho Ventures, Vivo Capital, Mission BioCapital, Aulis Capital, Codon Capital
$23M2023-07-20	EpiBiologics	Digitalis Ventures, Taiho Ventures, Codon Capital
$93M2022-11-15	Bonum Therapeutics	Codon Capital, RiverVest Venture Partners, Roche Venture Fund, Digitalis Ventures, Vivo Capital, 503 Partners (formerly 3x5 Partners)

SHOW MORE